Adebrelimab plus apatinib and SOX (AASOX) as conversion therapy for borderline resectable gastric cancer: a single-arm, single-centre, exploratory phase II study
A dual-targeting nitrogen mustard-class I HDAC inhibitor hybrid molecule is superior to the combination of an HDAC inhibitor plus chlorambucil in glioblastoma cells